Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma (PaTK02)
Neoadjuvant CAN-2409 Plus Prodrug in Combination With Chemoradiation or Stereotactic Body Radiation Therapy for Borderline Resectable Pancreatic Adenocarcinoma
Sponsor: Candel Therapeutics, Inc.
A PHASE2 clinical study on Borderline Resectable Pancreatic Adenocarcinoma, this trial is ongoing. The trial is conducted by Candel Therapeutics, Inc. and has accumulated 15 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
15 versions recorded-
Sep 2024 — Present [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Feb 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Nov 2023 — Feb 2024 [monthly]
Active Not Recruiting PHASE2
-
Jun 2023 — Nov 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 10 earlier versions
-
Jan 2023 — Jun 2023 [monthly]
Recruiting PHASE2
-
Jan 2021 — Jan 2023 [monthly]
Recruiting PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Aug 2020 — Oct 2020 [monthly]
Recruiting PHASE2
-
Jun 2020 — Aug 2020 [monthly]
Recruiting PHASE2
-
Aug 2019 — Jun 2020 [monthly]
Recruiting PHASE2
Phase: PHASE1_PHASE2 → PHASE2
-
Jun 2018 — Aug 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2017 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2017 — Jun 2017 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Oct 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Candel Therapeutics, Inc.
- Mayo Clinic
For direct contact, visit the study record on ClinicalTrials.gov .